Huhtamaki India Limited has informed the Exchange about Transcript
HUHTAMAKI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Huhtamaki India reported Q1 CY26 results with net sales flat (up 10 bps YoY) but EBITDA up 25%, driven by focus on higher-value business and operational efficiency. EBIT rose 4% to 8% margin, though impacted by a one-time INR 88 million depreciation charge (prior-year accounting error correction). Excluding this charge, EBIT would have risen 23.1%. The new CFO Amit Gupta joined last month from Procter & Gamble Health. On raw materials, the company sees low-to-medium double-digit cost inflation since late March due to geopolitical factors but has swiftly passed through costs to customers with no availability issues. Management highlighted sustainability progress including 67% improvement in safety incidents and a new solar captive project. The company has no immediate plans for acquisitions, focusing on organic growth. An ECB loan repayment to parent was amended from February 2026 to June 2027 per RBI guidelines.
The company's focus on profitable growth and margin expansion is showing results, suggesting operational strength. The swift raw material cost pass-through demonstrates pricing power and customer relationships. The one-time depreciation adjustment is non-cash but temporarily impacts reported profits. The stock trading near 1x book suggests market skepticism despite improving fundamentals.